id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-305816-06lddk87	Musarrat, Farhana	The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections	2020-05-17		.txt	text/plain	3227	189	52	title: The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections A systematic screening of several drugs including cardiac glycosides and kinase inhibitors and inhibitors of human immunodeficiency virus (HIV) entry revealed that only the FDA‐approved HIV protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited S‐n‐ and S‐o‐mediated cell fusion with complete inhibition at a 10‐μM concentration. 26 In addition to its potent activity against the HIV protease, nelfinavir mesylate was found to produce multiple effects on cellular processes including the induction of apoptosis and necrosis as well as induction of cell-protective mechanisms, including cell cycle retardation and the unfolded protein response. HRP, horseradish peroxidase; SARS CoV, severe acute respiratory syndrome coronavirus; Sn, S-new Recently, it was shown that a peptide that targeted the S-n HR1 domain S inhibited SARS-CoV-2 virus replication, virus entry, and virus-induced cell fusion. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides	./cache/cord-305816-06lddk87.txt	./txt/cord-305816-06lddk87.txt